- Title
- T2-low: what do we know?: Past, present, and future of biologic therapies in noneosinophilic asthma
- Creator
- Niessen, Natalie M.; Fricker, Michael; McDonald, Vanessa M.; Gibson, Peter G.
- Relation
- Annals of Allergy, Asthma, & ImmunologyAnnals of Allergy, Asthma, & Immunology Vol. 129, Issue 2, p. 150-159
- Publisher Link
- http://dx.doi.org/10.1016/j.anai.2022.04.020
- Publisher
- Elsevier
- Resource Type
- journal article
- Date
- 2022
- Description
- T2-low asthma is an often severe asthma subtype with limited treatment options and biologic therapeutics are lacking. Several monoclonal antibodies (mAbs) targeting non-T2 cytokines were previously reported to be ineffective in asthma. These trials often investigated heterogeneous asthma populations and negative outcomes could be related to unsuitable study cohorts. More tailored approaches in selecting participants based on specific biomarkers have been beneficial in treating severe T2-high asthma. Similarly, mAbs previously deemed ineffective bear the potential to be useful when administered to the correct target population. Here, we review individual clinical trials conducted between 2005 and 2021 and assess the suitability of the selected cohorts, whether study end points were met, and whether outcome measures were appropriate to investigate the effectiveness of the respective drug. We discuss potential target groups within the T2-low asthma population and suggest biomarkers that may predict a treatment response. Furthermore, we assess whether biomarker-guided approaches or subgroup analyses were associated with more positive study outcomes. The mAbs directed against alarmins intervene early in the inflammatory cascade and are the first mAbs found to have efficacy in T2-low asthma. Several randomized controlled trials performed predefined subgroup analyses that included T2-low asthma. Subgroup analyses were associated with positive outcomes and were able to reveal a stronger response in at least 1 subgroup. A better understanding of T2-low subgroups and specific biomarkers is necessary to identify the most responsive target population for a given mAb.
- Subject
- severe asthma; monoclonal antibodies; clinical trials; biomarkers; SDG 3; Sustainable Development Goals
- Identifier
- http://hdl.handle.net/1959.13/1487634
- Identifier
- uon:52202
- Identifier
- ISSN:1081-1206
- Language
- eng
- Reviewed
- Hits: 276
- Visitors: 274
- Downloads: 0
| Thumbnail | File | Description | Size | Format |
|---|